Essai clinique 2025-524079-22-00 · KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC)
Recherche en oncologie
19/10/2026
2025-524079-22-00 — est «autorisé» sur CTIS (EU Clinical Trials Information System).
Essai clinique 2025-524079-22-00 (phase III) est «autorisé» sur CTIS (EU Clinical Trials Information System).
Pathologie: KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) · Interventions enregistrées: Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, ASP3082 · Dates enregistrées (source): 2026-10-12, 2026-10-14.
Source: https://euclinicaltrials.eu/ctis-public/view/2025-524079-22-00